Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Recurrence 3Neoplasms 3Glioma 3Triple Negative Breast Neoplasms 2Sarcoma 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Prostatic Neoplasms 1Paraproteinemias 1Ovarian Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms, Neuroepithelial 1Medulloblastoma 1Lymphoproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1Hodgkin Disease 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Neoplasms × CLR1404 × Clear all
NCT02952508 2026-03-18

CLOVER-WaM

Cellectar Biosciences, Inc.

Phase 2 Active not recruiting
120 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT01495663 2015-02-26

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Cellectar Biosciences, Inc.

Phase 1 Completed
12 enrolled
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT00925275 2010-05-04

Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors

Cellectar, Inc

Phase 1 Completed
9 enrolled

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡